Research Topics
| Michael J DetkeSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studiesJean Endicott
New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
J Clin Psychiatry 68:518-24. 2007..The present work examined the efficacy of duloxetine treatment for improving functional outcomes for patients with GAD in 3 independent clinical studies...- Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trialMichael J Detke
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
J Clin Psychiatry 63:308-15. 2002..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms... - Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depressionMichael J Detke
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
J Psychiatr Res 36:383-90. 2002..There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD... - Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trialMichael J Detke
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Eur Neuropsychopharmacol 14:457-70. 2004..This placebo-controlled study assesses the safety and efficacy of duloxetine (80 or 120 mg/day) and paroxetine (20 mg QD) during an initial 8-week acute phase and subsequent 6-month continuation phase treatment of MDD... - Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Craig H Mallinckrodt
Lilly Research Laboratories, Indianapolis, Ind 46285, USA
Neuropsychobiology 56:73-85. 2007.... - Simple options for improving signal detection in antidepressant clinical trialsCraig H Mallinckrodt
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Psychopharmacol Bull 40:101-14. 2007..Researchers may be able to take advantage of these easy-to-implement methods while we wait for further improvements in other areas... - Duloxetine vs. placebo in patients with painful diabetic neuropathyDavid J Goldstein
PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
Pain 116:109-18. 2005..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain... 
Efficacy and safety of duloxetine in patients with chronic low back painVladimir Skljarevski
Lilly Research Laboratories, Indianapolis, IN, USA
Spine (Phila Pa 1976) 35:E578-85. 2010..This was a randomized, double-blind, placebo-controlled clinical trial...
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsCraig H Mallinckrodt
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
BMC Psychiatry 4:26. 2004..We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy...- Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetineDavid J Goldstein
PRN Consulting, Indianapolis, IN, USA
J Clin Psychopharmacol 24:389-99. 2004..031). Hypertension incidence was not affected by any treatment. CONCLUSION: Duloxetine therapy was efficacious for emotional and physical symptoms of depression, with a selective serotonin reuptake inhibitor-like profile of side effects... - Effects of duloxetine on painful physical symptoms associated with depressionDavid J Goldstein
Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
Psychosomatics 45:17-28. 2004..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression... - The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depressionFrank P Bymaster
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
Curr Pharm Des 11:1475-93. 2005..More importantly, duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms... - Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic painVladimir Skljarevski
Eli Lilly and Company, Indianapolis, Indiana, USA
Diabetes Metab Res Rev 25:623-31. 2009..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)... - A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressantCraig Mallinckrodt
Eli Lilly and Company, Indianapolis, IN 46285, USA
Pharm Stat 6:9-22. 2007..Our case study suggests that the DBLE design can provide definitive answers to important questions and may be a useful design for assessing long-term treatment effects... - Use of effect size to determine optimal dose of duloxetine in major depressive disorderYili L Pritchett
Eli Lilly and Company, Lilly Corporate Center, DC 6112, Indianapolis, IN 46285, USA
J Psychiatr Res 41:311-8. 2007..In addition, duloxetine-treated patients have significantly higher remission and response rates compared with placebo. The objective of this analysis is to determine the optimal dose of duloxetine in MDD... - Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trialsBeth A Pangallo
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Curr Med Res Opin 26:2643-51. 2010.... - Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trialDavid G S Perahia
Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
J Clin Psychiatry 70:706-16. 2009..To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD)... - Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled studyDavid G Perahia
Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
Br J Psychiatry 188:346-53. 2006..Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission... - Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment scheduleCraig H Mallinckrodt
Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
Stat Med 25:2384-97. 2006..Additional research is needed to assess whether these findings hold in data with drop-out and across definitions of onset... 
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgiaAmy S Chappell
Lilly Research Laboratories, Indianapolis, IN, USA
Int J Gen Med 1:91-102. 2009..Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment...- Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 yearsVivien K Burt
Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
Psychosomatics 46:345-54. 2005..Duloxetine (60 mg/day) was demonstrated to be an effective treatment for major depressive disorder in this cohort of women ages 40-55 years... - Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depressionRichard C Shelton
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Int Clin Psychopharmacol 22:348-55. 2007.... - Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 27:672-6. 2007.... - A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorderLesley M Arnold
University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
Arthritis Rheum 50:2974-84. 2004..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder... - Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trialI Jon Russell
University of Texas Health Science Center, San Antonio, TX, USA
Pain 136:432-44. 2008..Study results demonstrated that duloxetine at doses of 60 mg/day and 120 mg/day appears to be safe and efficacious in patients with fibromyalgia... - Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetineMadhukar H Trivedi
Mood Disorders Program and Clinic, University of Texas Southwestern Medical School, Dallas, TX 75235 9119, USA
Int Clin Psychopharmacol 23:161-9. 2008..In summary, the data presented in this report provide clinical evidence of a mechanism for duloxetine involving both 5-HT and NE reuptake inhibition in humans and are consistent with preclinical evidence for 5-HT/NE reuptake inhibition... - The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?Maurizio Fava
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
J Clin Psychiatry 65:521-30. 2004..It was hypothesized that resolution of both psychological and physical symptoms of depression would predict a higher percentage of patients achieving remission... - Duloxetine in treatment of anxiety symptoms associated with depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
Depress Anxiety 18:53-61. 2003..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies... - Duloxetine in the treatment of major depressive disorder: an open-label studyJames I Hudson
McLean Hospital, Belmont, MA, USA
BMC Psychiatry 7:43. 2007..In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined... - Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studiesStephen K Brannan
Cyberonics, Houston, TX, USA
J Psychiatr Res 39:161-72. 2005..However, results from the present investigation may be useful to clinicians in consideration of treatment options for individual patients... - Time course of depression-symptom improvement during treatment with duloxetineRobert M A Hirschfeld
University of Texas Medical Branch, Galveston, TX 77555 0188, USA
Depress Anxiety 21:170-7. 2005..These results may help clinicians establish more accurate expectations regarding treatment with duloxetine... - Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depressionDavid L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
J Affect Disord 87:115-9. 2005..This study investigated the rate of hypomania, mania, and hypomanic-like symptoms observed during treatment with duloxetine in patients with major depression... - Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorderPedro L Delgado
Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA
J Clin Psychiatry 66:686-92. 2005..However, the incidence of acute treatment-emergent dysfunction for duloxetine was significantly lower than that observed for paroxetine... - Management of depression relapse: re-initiation of duloxetine treatment or dose increaseMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, ACC 812, Boston, MA 02114, United States
J Psychiatr Res 40:328-36. 2006..Patients relapsing on duloxetine 60 mg QD benefited from an increase to 60 mg BID. These duloxetine doses were well tolerated and effective, and appear appropriate for MDD patients requiring treatment of relapse... - Duloxetine for the treatment of major depressive disorder in older patientsJ Craig Nelson
Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
Am J Geriatr Psychiatry 13:227-35. 2005..CONCLUSIONS: In these two investigations, duloxetine 60 mg/day was an efficacious treatment for MDD and also alleviated pain symptoms in depression patients age 55 and older... - Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialMoira Rynn
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Depress Anxiety 25:182-9. 2008..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD... - Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrineMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
J Clin Psychopharmacol 25:132-40. 2005..The cardiovascular effects of duloxetine appear to be comparable with medications considered to be first-line options for depression... - Is PTSD caused by traumatic stress?J Alexander Bodkin
Clinical Psychopharmacology Research Program, McLean Hospital, Belmont, MA 02478, USA
J Anxiety Disord 21:176-82. 2007..This equivalence suggests that in a treatment-seeking population, caution should be exercised in attributing the PTSD syndrome to trauma... - Antidepressant-like effects of cytidine in the forced swim test in ratsWilliam A Carlezon
Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA
Biol Psychiatry 51:882-9. 2002..At antidepressant doses, cytidine lacks stimulant and rewarding properties. This is the first report of potential antidepressant effects of cytidine... - The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibitionStephane Chalon
Neuropsychopharmacology 26:698-9; author reply 700-1. 2002